As determined by mass cytometry of melanoma tissues using a panel of 43 markers, CD8+/CD4+EOMES+CD69+CD45RO+ effector memory T cells were significantly more abundant in responders of combined immunotherapy compared with non-responders [28]. The gene discussed is CD8A; the disease is melanoma.